HealthDay News — For patients with type 2 diabetes, the risk of acute myocardial infarction (AMI) is not significantly different for long-acting insulin analogs versus other basal insulin therapies, ...

People with diabetes who suffer a myocardial infarction face markedly worse outcomes than non-diabetic individuals. Diabetes doubles the risk of early mortality and sustains elevated rates of heart ...

Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular ...

Clinical auditing reveals significant misclassification in administrative codes for myocardial infarction (MI), with only 39% of type 1 (T1MI) codes and 72% of type 2 (T2MI) codes for the condition ...